# Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides

> **NCT04676087** · PHASE1,PHASE2 · TERMINATED · sponsor: **Emory University** · enrollment: 5 (actual)

## Conditions studied

- Mycosis Fungoides
- Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
- Sezary Syndrome

## Interventions

- **PROCEDURE:** Extracorporeal Photopheresis
- **BIOLOGICAL:** Mogamulizumab
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT04676087
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-21
- **Primary completion:** 2023-10-11
- **Final completion:** 2023-10-11
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2024-08-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04676087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04676087, "Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04676087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*